Seladelpar Recruiting Phase 3 Trials for Primary Biliary Cholangitis Treatment

Indications	Status	Purpose	Phase
DBCOND0080519 (Primary Biliary Cholangitis)	Recruiting	Treatment	3

clinicaltrials.gov Identifier	Title	Drugs
NCT03301506	Seladelpar in Subjects With Primary Biliary Cholangitis (PBC)	Seladelpar (DB12390)
NCT06051617	Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis	Seladelpar (DB12390)
NCT06060665	IDEAL: Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA)	Seladelpar (DB12390)